Alcon employs former Novartis CFO
This article was originally published in Clinica
Executive Summary
Eye care company Alcon has appointed Robert Karsunky to the role of CFO. Mr Karsunky previously held the same position at Novartis’s consumer health division. Novartis has a 77% stake in Alcon, and is currently battling it out with shareholders of the Huenenberg, Switzerland-based firm to buy the remaining 23%. Mr Karsunky will take up his new position on 1 November, when he will replace Richard Croarkin. Mr Croarkin will remain a member of the firm’s executive leadership team until 30 November to help with the transition, after which he will return to a financial position at Nestlé, where he was employed from 1994 until 2007.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals